

Litigation	Reference Product	Biosimilar	Filing Date	Complaint Type	Status
<i>AbbVie v. Amgen</i> 1:16-cv-00666 (D. Del.)	Humira® (adalimumab)	Amjevita™ (adalimumab-atto) Approved 9/23/2016 Settlement market entry 1/31/2023	8/4/2016	Infringement	Settled 9/28/2017
<i>AbbVie v. Boehringer Ingelheim</i> 1:17-cv-01065 (D. Del.)	Humira® (adalimumab)	Cyltezo® (adalimumab-adbm) Approved 8/25/2017, Interchangeable 10/15/2021 Settlement market entry 7/1/2023	8/2/2017	Infringement	Settled 5/15/2019
<i>AbbVie v. Sandoz</i> 3:18-cv-12668 (D.N.J.)	Humira® (adalimumab)	Hyrimoz™ (adalimumab-adaz) Approved 10/30/2018 Settlement market entry 9/30/2023	8/10/2018	Infringement	Settled 10/16/2018
<i>Coherus v. Amgen</i> 1:19-cv-00139 (D. Del.)	Biosimilar- Biosimilar	Yusimry™ (adalimumab-aqvh) Settlement market entry 12/15/2023 Amjevita™ (adalimumab-atto) Approved 9/23/2016 Settlement market entry 9/30/2023	1/24/2019	Infringement	Settled 11/26/2019
<i>AbbVie v. Alvotech</i> 1:21-cv-02258 (N.D. Ill.)	Humira® (adalimumab)	AVT02 (adalimumab) aBLA Pending	4/27/2021	Infringement	Settled 3/9/2022
<i>AbbVie v. Alvotech</i> 1:21-cv-05645 (N.D. Ill.)	Humira® (adalimumab)	AVT02 (adalimumab) aBLA Pending	5/11/2021	Declaratory Judgment	Voluntarily dismissed 11/5/2021
<i>AbbVie v. Alvotech</i> 1:21-cv-02899 (N.D. Ill.)	Humira® (adalimumab)	AVT02 (adalimumab) aBLA Pending	5/28/2021	Infringement	Settled 3/9/2022
<i>Regeneron v. Mylan</i> 1:22-cv-00061 (N.D.W.Va.)	Eylea® (aflibercept)	M710 (aflibercept) aBLA Pending	8/2/2022	Infringement	Ongoing

Litigation	Reference Product	Biosimilar	Filing Date	Complaint Type	Status
<i>Genentech v. Amgen</i> 1:17-cv-00165 (D. Del.)	Avastin® (bevacizumab)	Mvasi® (bevacizumab- awwb) Approved 9/14/2017 Launched 7/2019	2/15/2017	Declaratory judgment (failure to comply with BPCIA)	Dismissed 3/1/2017- Patent dance not mandatory
<i>Amgen v. Genentech</i> 2:17-cv-07349 (C.D. Cal.)	Avastin® (bevacizumab)	Mvasi® (bevacizumab- awwb) Approved 9/14/2017 Launched 7/2019	10/6/2017	Declaratory judgment	Dismissed 2/2/2018- Declaratory judgment not available to biosimilar
<i>Genentech v. Amgen</i> 1:17-cv-01407 (D. Del.)	Avastin® (bevacizumab)	Mvasi® (bevacizumab- awwb) Approved 9/14/2017 Launched 7/2019	10/6/2017	Infringement	Settled 7/7/2020
<i>Genentech v. Amgen</i> 1:17-cv-01471 (D. Del.)	Avastin® (bevacizumab)	Mvasi® (bevacizumab- awwb) Approved 9/14/2017 Launched 7/2019	10/18/2017	Infringement	Consolidated with 1:17-cv-01407 (D. Del.); Settled 7/7/2020
<i>Genentech v. Immunex</i> 1:19-cv-00602 (D. Del.) Fed. Cir. 19-2155	Avastin® (bevacizumab)	Mvasi® (bevacizumab- awwb) Approved 9/14/2017 Launched 7/2019	3/29/2019	Infringement	District Court- Temporary Restraining Order and Motion to Enforce Statutory Prohibition on Commercial Marketing denied 7/18/2019; Settled 7/7/2020 Appeal (TRO and Commercial Marketing)- Affirmed 7/6/2020
<i>Genentech v. Pfizer</i> 1:19-cv-00638 (D. Del.)	Avastin® (bevacizumab)	Zirabev® (bevacizumab-bvzr) Approved 6/27/2019 Launched 12/2019	4/5/2019	Infringement	Settled 9/20/2019
<i>Genentech v. Samsung Bioepis</i> 1:20-cv-00859 (D. Del.)	Avastin® (bevacizumab)	SB8 (bevacizumab) aBLA Pending	6/28/2020	Infringement	Settled 9/8/2022

Litigation	Reference Product	Biosimilar	Filing Date	Complaint Type	Status
<i>Genentech v. Centus Biotherapeutics</i> 2:20-cv-00361 (E.D. Tex.)	Avastin® (bevacizumab)	FKB238 (bevacizumab) aBLA Pending	11/12/2020	Infringement	Settled 7/2/2021
<i>Amgen v. Hospira</i> 1:15-cv-00839 (D. Del.) Fed. Cir. 16-2179 Fed. Cir. 19-1067 Fed. Cir. 19-1102	Epogen® / Procrit® (epoetin alfa)	Retacrit® (epoetin alfa) Approved 5/15/2018 Launched 11/2018	9/18/2015	Infringement; Declaratory judgment (failure to comply with BPCIA)	District Court- 9/26/2017: Jury Verdict (some claims valid and infringed; some claims invalid) Appeal 16-2179 (motion to compel manufacturing information on patents not asserted)- 8/10/2017: Dismissed for lack of jurisdiction; Petition for writ of mandamus denied Appeal 19-1067 and Cross Appeal 19-1102 (final judgment)- 12/16/2019: Affirmed; 3/16/2020: Petition for en banc rehearing denied
<i>Sandoz v. Amgen</i> 3:13-cv-02904 (N.D. Cal.) Fed. Cir. 14-1693	Enbrel® (etanercept)	Erelzi® (etanercept-szzs) Approved 8/30/2016	6/24/2013	Declaratory Judgment	District Court- Dismissed for lack of subject matter jurisdiction 11/19/2013 Appeal- Affirmed 12/5/2014
<i>Amgen v. Sandoz</i> 2:16-cv-01118 (D.N.J.) Fed. Cir. 20-1037 Sup. Ct. 20-1110	Enbrel® (etanercept)	Erelzi® (etanercept-szzs) Approved 8/30/2016	2/26/2016	Infringement	District Court- 8/9/2019: '182 patent claims 11-23 and 35-36 and '522 patent claims 3, 8, and 10 not invalid. Parties previously stipulated to infringement. Permanent injunction issued. Appeal- Affirmed 7/1/2020; Request for <i>en banc</i> rehearing denied 9/29/2020 Supreme Court- Certiorari denied 5/17/2021
<i>Amgen v. Samsung Bioepis</i> 2:19-cv-11755 (D.N.J.)	Enbrel® (etanercept)	Eticovo™ (etanercept-ykro) Approved 4/25/2019	4/30/2019	Infringement	11/3/2021- Final judgment in favor of Amgen, Permanent injunction issued (will terminate when U.S. Patent Nos. 8,063,182 and 8,163,522 expire on April 24, 2029)

Litigation	Reference Product	Biosimilar	Filing Date	Complaint Type	Status
<i>Amgen v. Sandoz</i> 3:14-cv-04741 (N.D. Ca.) Fed. Cir. 15-1499 S. Ct. 15-1039 S. Ct. 15-1195 Fed. Cir. 18-1551	Neupogen® (filgrastim)	Zarxio® (filgrastim-sndz) Approved 3/6/2015 Launched 9/2015	10/24/2014	Infringement; BPCIA Interpretation	BPCIA Interpretation: District Court- 3/19/2015: Patent dance not mandatory, 180-day notice can be given before FDA approval Appeal 15-1499- 7/21/2015: Affirmed patent dance not mandatory, but 180-day notice cannot be given before FDA approval. S. Ct. Appeals 15-1039 and 15-1195- 6/12/2017: Agreed with District Court that 180-day notice can be given before FDA approval, no injunction available under federal law to force compliance with patent dance; remanded to determine whether state law provided injunction Appeal 15-1499 (on remand from S. Ct.)- 12/14/2017: State law did not provide injunction for failure to comply with patent dance Infringement/Validity: District Court- 1/8/2018: Summary judgment of non-infringement and dismissal of invalidity counterclaims Appeal 18-1551- 5/8/2019: Affirmed summary judgment; 9/3/2019 Petition for rehearing <i>en banc</i> granted-in-part
<i>Amgen v. Apotex</i> 0:15-cv-62081 (S.D. Fla.) Fed. Cir. 17-1010	Neupogen® (filgrastim)	Grastofil™ (filgrastim) aBLA Pending	10/2/2015	Infringement	Consolidated with 0:15-cv-61631 (S.D. Fla.) District Court- 9/6/2016: Patent not infringed, not unenforceable, and counterclaims of invalidity dismissed Appeal- Affirmed 11/13/2017
<i>Amgen v. Adello</i> 2:18-cv-03347 (D.N.J.)	Neupogen® (filgrastim)	Releuko™ (filgrastim) Approved 2/25/2022 Launched 11/2022	3/8/2018	Infringement	Settled 11/25/2019
<i>Amgen v. Pfizer</i> 1:18-cv-01064 (D. Del.)	Neupogen® (filgrastim)	Nivestym® (filgrastim-aafi) Approved 7/20/2018 Launched 10/2018	7/18/2018	Infringement	Settled 9/8/2021
<i>Amgen v. Tanvex</i> 3:19-cv-01374 (S.D. Cal.)	Neupogen® (filgrastim)	TX-01 (filgrastim) aBLA Pending	7/23/2019	Infringement	Settled 12/20/2019

Litigation	Reference Product	Biosimilar	Filing Date	Complaint Type	Status
<i>Amgen v. Pfizer</i> 1:20-cv-00561 (D. Del.)	Neupogen® (filgrastim)	Nivestym® (filgrastim-aafi) Approved 7/20/2018 Launched 10/2018	4/24/2020	Infringement	Settled 9/8/2021
<i>Amgen v. Apotex</i> 0:18-cv-61828 (S.D. Fla.)	Neupogen® (filgrastim) / Neulasta® (pegfilgrastim)	Grastofil™ (filgrastim) aBLA Pending Lapelga™ (pegfilgrastim) aBLA Pending	8/7/2018	Infringement	Settled 11/15/2019
<i>Sandoz v. Amgen</i> 3:19-cv-00977 (N.D. Cal.)	Neupogen® (filgrastim) / Neulasta® (pegfilgrastim)	Zarxio® (filgrastim-sndz) Approved 3/6/2015 Launched 9/2015 Ziextenzo® (pegfilgrastim-bmez) Approved 11/4/2019 Launched 11/2019	2/21/2019	Declaratory judgment	Related to 3:14-cv-04741 (N.D. Cal.) and 3:16-cv-02581 (N.D. Cal.) Voluntarily dismissed 5/13/2019
<i>Amgen v. Apotex</i> 0:15-cv-61631 (S.D. Fla.) Fed. Cir. 16-1308 S. Ct. 16-332 Fed. Cir. 17-1010	Neulasta® (pegfilgrastim)	Lapelga™ (pegfilgrastim) aBLA Pending	8/6/2015	Infringement	Preliminary Injunction District Court- 12/9/2015: Granted preliminary injunction preventing launch until 180 days after post-licensure notice of commercial marketing Appeal 16-1308- Affirmed 7/5/2016 S. Ct.- Cert denied 12/12/2016 Infringement/Validity: District Court- 9/6/2016: Not infringed, not unenforceable, invalidity dismissed Appeal 17-1010- Affirmed 11/13/2017
<i>Amgen v. Sandoz</i> 2:16-cv-01276 (D.N.J.)	Neulasta® (pegfilgrastim)	Ziextenzo® (pegfilgrastim-bmez) Approved 11/4/2019 Launched 11/2019	3/4/2016	Declaratory judgment (BPCIA non-compliance)	Dismissed 3/31/2017
<i>Amgen v. Sandoz</i> 3:16-cv-02581 (N.D. Cal.) Fed. Cir. 18-1552	Neulasta® (pegfilgrastim)	Ziextenzo® (pegfilgrastim-bmez) Approved 11/4/2019 Launched 11/2019	5/12/2016	Infringement	District Court- Summary judgment of non-infringement 12/19/2017 Appeal (consolidated with 18-1551)- Affirmed 5/8/2019

Litigation	Reference Product	Biosimilar	Filing Date	Complaint Type	Status
<i>Amgen v. Coherus</i> 1:17-cv-00546 (D. Del.) Fed. Cir. 18-1993	Neulasta® (pegfilgrastim)	Udenyca® (pegfilgrastim-cbqv) Approved 11/2/2018 Launched 1/2019	5/10/2017	Infringement	District Court- Dismissed for failure to state a claim 4/18/2018 Appeal- Affirmed 7/29/2019
<i>Amgen v. Mylan</i> 2:17-cv-01235 (W.D. Pa.)	Neulasta® (pegfilgrastim)	Fulphila® (pegfilgrastim-jmdb) Approved 6/4/2018 Launched 7/2018	9/22/2017	Infringement	Terminated 9/16/2019- Stipulation of non-infringement
<i>Amgen v. Hospira</i> 1:20-cv-00201 (D. Del.)	Neulasta® (pegfilgrastim)	Nyvepria® (pegfilgrastim-apgf) Approved 6/10/2020 Launched 1/2021	2/11/2020	Infringement	Settled 3/21/2022
<i>Celltrion v. Janssen</i> 1:14-cv-11613 (D. Mass.)	Remicade® (infliximab)	Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016	3/31/2014	Declaratory judgment (prior to aBLA filing)	Voluntarily dismissed 10/23/2014 (Biosimilar called Remsima® in complaint, but has since been named Inflectra® in the US)
<i>Celltrion v. The Kennedy Trust for Rheumatology Research</i> 1:14-cv-02256 (S.D.N.Y.)	Remicade® (infliximab)	Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016	3/31/2014	Declaratory judgment (prior to aBLA filing)	Dismissed for lack of subject matter jurisdiction 12/1/2014
<i>Hospira v. Janssen</i> 1:14-cv-07049 (S.D.N.Y.)	Remicade® (infliximab)	Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016	8/29/2014	Declaratory judgment (prior to aBLA filing)	Dismissed for lack of subject matter jurisdiction 12/1/2014
<i>Janssen v. Celltrion</i> 1:15-cv-10698 (D. Mass.) Fed. Cir. 17-1120	Remicade® (infliximab)	Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016	3/6/2015	Infringement	District Court- Partial judgment 9/26/2016 finding '471 patent claims invalid for obviousness-type double patenting; Remainder of case ongoing Appeal (double patenting)- 1/23/2018: Dismissed as moot because reexam appeal 17-1257 affirmed claims were unpatentable

Litigation	Reference Product	Biosimilar	Filing Date	Complaint Type	Status
<i>Janssen v. Celltrion</i> 1:16-cv-11117 (D. Mass.)	Remicade® (infliximab)	Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016	6/14/2016	Infringement	Dismissed 8/7/2017. Infringement issues will be litigated in 1:17-cv-11008 (D. Mass.)
<i>Janssen v. Samsung Bioepis</i> 2:17-cv-03524 (D.N.J.)	Remicade® (infliximab)	Renflexis® (infliximab-abda) Approved 4/21/2017 Launched 7/2017	5/17/2017	Infringement	Stipulated dismissal 11/30/2017
<i>Janssen v. Celltrion</i> 1:17-cv-11008 (D. Mass.) Fed. Cir. 18-2321 Fed. Cir. 18-2350	Remicade® (infliximab)	Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016	5/31/2017	Infringement	District Court- Summary judgment of non-infringement 7/31/2018 Appeal 18-2321 and Cross-Appeal 18-2350- Affirmed 3/5/2020
<i>Sanofi-Aventis v. Eli Lilly</i> 1:14-cv-00113 (D. Del.)	Lantus® (insulin glargine)	Basaglar® (insulin glargine) Approved 12/16/2015 Launched 12/2016	1/30/2014	Infringement	Settled 9/28/2015
<i>Sanofi-Aventis v. Eli Lilly</i> 1:14-cv-00884 (D. Del.)	Lantus® (insulin glargine)	Basaglar® (insulin glargine) Approved 12/16/2015 Launched 12/2016	7/7/2014	Infringement	Settled 5/8/2015
<i>Sanofi-Aventis v. Merck</i> 1:16-cv-00812 (D. Del.)	Lantus® (insulin glargine)	Lusduna™ Nexvue™ (insulin glargine) Tentative Approval 7/20/2017	9/16/2016	Infringement	Dismissed 10/29/2018 – Merck no longer pursuing product
<i>Sanofi-Aventis v. Merck</i> 2:17-cv-05914 (D.N.J.)	Lantus® (insulin glargine)	Lusduna™ Nexvue™ (insulin glargine) Tentative Approval 7/20/2017	8/8/2017	Infringement	Dismissed 11/13/2018 – Merck no longer pursuing product
<i>Sanofi-Aventis v. Mylan</i> 2:17-cv-09105 (D.N.J.) Fed. Cir. 21-1262	Lantus® (insulin glargine)	Semglee® (insulin glargine-yfng) Approved 6/11/2020, Launched 8/2020; Interch. Approved 7/28/2021, Launched 11/2021	10/24/2017	Infringement	District Court- 3/9/2020: Claims 21, 22, 25 and 30 of '844 patent not infringed, and invalid for lack of written description Appeal- Dismissed as moot 12/29/2021
<i>Biogen v. Sandoz</i> 1:22-cv-01190 (D. Del.)	Tysabri® (natalizumab)	PB006 (natalizumab) aBLA Pending	9/9/2022	Infringement	Ongoing

Litigation	Reference Product	Biosimilar	Filing Date	Complaint Type	Status
<i>Genentech v. Sandoz</i> 1:17-cv-13507 (D.N.J.)	Rituxan® (rituximab)	Rixathon® (rituximab) aBLA Pending	12/21/2017	Infringement	Stipulated dismissal 12/6/2018. Sandoz no longer pursuing its biosimilar application.
<i>Celltrion v. Genentech</i> 4:18-cv-00276 (N.D. Cal.) Fed. Cir. 18-2161	Rituxan® (rituximab)	Truxima® (rituximab-abbs) Approved 11/28/2018 Launched 11/2019	1/1/2018	Declaratory judgment	District Court- Dismissed for failure to state a claim 5/10/2018 Appeal voluntarily dismissed 11/30/2018
<i>Genentech v. Celltrion</i> 1:18-cv-00574 (D.N.J.)	Rituxan® (rituximab)	Truxima® (rituximab-abbs) Approved 11/28/2018 Launched 11/2019	1/12/2018	Infringement	Settled 11/1/2018
<i>Genentech v. Celltrion</i> 1:18-cv-11553 (D.N.J.)	Rituxan® (rituximab)	Truxima® (rituximab-abbs) Approved 11/28/2018 Launched 11/2019	7/11/2018	Infringement	Related to 1:18-cv-00574 (D.N.J.) Settled 11/1/2018
<i>Genentech v. Pfizer</i> 1:17-cv-01672 (D. Del.)	Herceptin® (trastuzumab)	Trazimera® (trastuzumab-qyyp) Approved 3/11/2019 Launched 2/2020	11/17/2017	Infringement	Settled 12/4/2018
<i>Celltrion v. Genentech</i> 4:18-cv-00274 (N.D. Cal.) Fed. Cir. 18-2160	Herceptin® (trastuzumab)	Herzuma® (trastuzumab-pkrb) Approved 12/14/2018 Launched 3/2020	1/11/2018	Declaratory judgment	District Court- Dismissed for failure to state a claim 5/10/2018 Appeal- Voluntarily dismissed 11/30/2018
<i>Genentech v. Celltrion</i> 1:18-cv-00095 (D. Del.)	Herceptin® (trastuzumab)	Herzuma® (trastuzumab-pkrb) Approved 12/14/2018 Launched 3/2020	1/12/2018	Infringement	Settled 12/27/2018

Litigation	Reference Product	Biosimilar	Filing Date	Complaint Type	Status
<i>Genentech v. Amgen</i> 1:18-cv-00924 (D. Del.) Fed. Cir. 19-2156	Herceptin® (trastuzumab)	Kanjinti® (trastuzumab-anns) Approved 6/13/2019 Launched 7/2019	6/21/2018	Infringement	District Court- Temporary Restraining Order and Preliminary Injunction denied 7/18/2019; Settled 7/7/2020 Appeal (TRO and PI)- Affirmed 3/6/2020
<i>Genentech v. Celltrion</i> 1:18-cv-01025 (D. Del.)	Herceptin® (trastuzumab)	Herzuma® (trastuzumab-pkrb) Approved 12/14/2018 Launched 3/2020	7/11/2018	Infringement	Consolidated with 1:18-cv-00095 (D. Del.), Settled 12/27/2018
<i>Genentech v. Samsung Bioepis</i> 1:18-cv-01363 (D. Del.)	Herceptin® (trastuzumab)	Ontruzant® (trastuzumab-dttb) Approved 1/18/2019 Launched 4/2020	9/4/2018	Infringement	Settled 7/1/2019
<i>Genentech v. Tanvex</i> 3:22-cv-00809 (S.D. Cal.)	Herceptin® (trastuzumab)	TX-05 (trastuzumab) aBLA pending	6/2/2022	Infringement	Ongoing
<i>Janssen v. Amgen</i> 1:22-cv-01549 (D. Del.)	Stelara® (ustekinumab)	ABP 654 (ustekinumab) aBLA pending	11/29/2022	Infringement	Ongoing